Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.72 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.72 |
| ▸ | HRH1 | P35367 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | HRH2 | P25021 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.72 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.72 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desfesoterodine SCHEMBL580657 | 1.00 | CHRM3 (0.72) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL29468683 | 1.00 | CHRM3 (0.72) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL209062 | 1.00 | CHRM3 (0.72) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL28757704 | 0.95 | CHRM3 (0.66) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL1808420 | 0.94 | CHRM2 (0.68) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL1811715 | 0.94 | CHRM2 (0.68) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL1808422 | 0.94 | CHRM2 (0.68) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL14696972 | 0.92 | CHRM2 (0.62) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL27490008 | 0.91 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL27491771 | 0.91 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3104848-B1 | INHALABLE PARTICLE FORMULATIONS COMPRISING AN ANTIMUSCARINIC AGENT | CRYSTEC LTD (GB) | 2020-05-06 | — | — | EP | claimed |
| US-20110105783-A1 | PROCESS FOR THE PREPARATION OF FESOTERODINE | DIPHARMA FRANCIS S.R.I. (IT) | 2011-05-05 | — | — | US | claimed |
| EP-2316817-A1 | Process for the preparation of fesoterodine | Dipharma Francis S.r.l. (IT) | 2011-05-04 | — | — | EP | claimed |
| US-11759420-B2 | Inhalable particles | CRYSTEC LTD (GB) | 2023-09-19 | — | — | US | disclosed |
| US-20220331243-A1 | INHALABLE PARTICLES | CRYSTEC LTD (GB) | 2022-10-20 | — | — | US | disclosed |
| US-11351115-B2 | Inhalable particles | CRYSTEC LTD (GB) | 2022-06-07 | — | — | US | disclosed |
| US-20170056325-A1 | Improvements Relating To Inhalable Particles | CRYSTEC LTD (GB) | 2017-03-02 | — | — | US | disclosed |
| US-20150306170-A1 | COMPOSITION FOR IMMEDIATE AND EXTENDED RELEASE | FERRING B.V. (NL) | 2015-10-29 | — | — | US | disclosed |
| EP-2922525-A1 | COMPOSITION FOR IMMEDIATE AND EXTENDED RELEASE | Ferring BV (NL) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079922-A1 | COMPOSITION FOR IMMEDIATE AND EXTENDED RELEASE | FERRING B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| US-8530691-B2 | Process for the preparation of fesoterodine | DIPHARMA FRANCIS S.R.L. (IT) | 2013-09-10 | — | — | US | disclosed |
| US-20030144352-A1 | Antimuscarinic aerosol | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
| US-20030118633-A1 | Combination therapy | PHARMACIA AB (SE) | 2003-06-26 | — | — | US | disclosed |
| WO-2003039524-A1 | ANTI-MUSCARINIC AGENT AND ESTROGEN-AGONIST FOR TREATING UNSTABLE OR OVERACTIVE BLADDER | PHARMACIA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-1254890-A1 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2002-11-06 | — | — | EP | disclosed |
| EP-1077912-B1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2002-07-03 | — | — | EP | disclosed |
| EP-1128819-A1 | NEW CONTROLLED RELEASE BEAD, A METHOD OF PRODUCING THE SAME AND MULTIPLE UNIT FORMULATION COMPRISING IT | Pharmacia AB (SE) | 2001-09-05 | — | — | EP | disclosed |
| EP-1077912-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000027364-A1 | NEW CONTROLLED RELEASE BEAD, A METHOD OF PRODUCING THE SAME AND MULTIPLE UNIT FORMULATION COMPRISING IT | PHARMACIA AB (SE) | 2000-05-18 | — | — | WO | disclosed |
| WO-1999058478-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105783-A1 | PROCESS FOR THE PREPARATION OF FESOTERODINE | HADHB, MAOB, FOSB | CHRM3 293/4885CHRM2 558/4885CHRM1 677/4885 |
| US-20030144352-A1 | Antimuscarinic aerosol | CHRM3, CHRM1, CHRM5 | CHRM3 1/4885CHRM2 4/4885CHRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.